TNGX

Tango Therapeutics, Inc.

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Rothenberg MaceDirector
--25k shares
Grant / ExerciseJun 5, 2026
$505.5K25k shares
$20.22
$19.65
Calhoun Lesley AnnDirector
--25k shares
Grant / ExerciseJun 5, 2026
$505.5K25k shares
$20.22
$19.65
Ketchum John BDirector
--25k shares
Grant / ExerciseJun 5, 2026
$505.5K25k shares
$20.22
$19.65
Lee SungDirector
--570 shares
Grant / ExerciseJun 5, 2026
Disclosure amount unavailable570 shares
--
$19.65
Rothenberg MaceDirector
--4k shares
Grant / ExerciseJun 5, 2026
Disclosure amount unavailable4k shares
--
$19.65
Calhoun Lesley AnnDirector
--4k shares
Grant / ExerciseJun 5, 2026
Disclosure amount unavailable4k shares
--
$19.65

News

zacks.comTNGX Stock Jumps 53% on Early Pancreatic Cancer Study Resultszacks.comJun 9seekingalpha.comTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcriptseekingalpha.comJun 8globenewswire.comTango Therapeutics Announces Proposed $500 Million Public Offeringglobenewswire.comJun 8invezz.comTango Therapeutics stock soars on promising pancreatic cancer datainvezz.comJun 8barrons.comTango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatmentbarrons.comJun 8